Premium
Lack of Effect of Cholestyramine on Phenytoin Bioavailability
Author(s) -
Barzaghi N.,
Monteleone M.,
Amione C.,
Lecchini S.,
Perucca E.,
Frigo G. M.
Publication year - 1988
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1988.tb05725.x
Subject(s) - cholestyramine , phenytoin , bioavailability , pharmacology , carbamazepine , pharmacokinetics , chemistry , crossover study , drug , drug interaction , anticonvulsant , oral administration , absorption (acoustics) , medicine , epilepsy , cholesterol , biochemistry , physics , alternative medicine , pathology , psychiatry , acoustics , placebo
The effect of cholestyramine (4 g qid for 5 days) on the kinetics of phenytoin (400 mg orally) was investigated in normal subjects. Apart from a trend toward faster phenytoin absorption, the serum level profile of the drug during concurrent cholestyramine coadministration was similar to that observed in a control session. Areas under the serum phenytoin concentration curves were virtually identical in the two occasions. It is concluded that cholestyramine does not significantly affect the bioavailability of a single dose of phenytoin.